SLC17A5 Antibody

What is SLC17A5 and what cellular functions does it perform?

SLC17A5 encodes a transmembrane protein called sialin that functions as a multifunctional anion transporter operating through two distinct mechanisms: proton-coupled anion cotransport and membrane potential-dependent anion transport . The protein serves as an electroneutral proton-coupled acidic monosaccharide symporter with a 1:1 sugar to proton stoichiometry . It exports glucuronic acid and free sialic acid derived from sialoglycoconjugate degradation out of lysosomes, driven by the outwardly directed lysosomal pH gradient . SLC17A5 may regulate lysosome function and metabolism of sialylated conjugates that impact oligodendrocyte lineage differentiation and myelinogenesis in the central nervous system . Additionally, it functions as an electrogenic proton-coupled nitrate symporter that transports nitrate ions across the basolateral membrane of salivary gland acinar cells with a 2:1 nitrate to proton stoichiometry, potentially contributing to nitrate clearance from serum . In the context of neurotransmission, it uses membrane potential to drive the uptake of acidic amino acids and peptides into synaptic vesicles and is responsible for synaptic vesicular storage of L-aspartate and L-glutamate in pinealocytes .

What are the common applications for SLC17A5 antibodies in research?

SLC17A5 antibodies are widely employed in multiple experimental applications. Western blot (WB) analysis is the most common application, with optimal dilution ranges typically between 1:500-1:2000 . Immunocytochemistry/Immunofluorescence (ICC/IF) is frequently used to visualize SLC17A5 localization within cells, as demonstrated by studies using methanol-fixed HepG2 cells with antibody dilutions of approximately 1:500 . Immunohistochemistry (IHC-P) on paraffin-embedded tissues is another established application, as shown in studies with BT474 xenograft tissues . Additionally, enzyme-linked immunosorbent assay (ELISA) has been employed in published research . When designing experiments, researchers should note that commercially available antibodies have been validated with human, mouse, and rat samples , though species-specific optimization may be necessary for optimal results.

How do I validate the specificity of an SLC17A5 antibody for my experimental system?

Validation of SLC17A5 antibody specificity requires a multi-faceted approach. First, conduct Western blot analysis using positive controls where SLC17A5 expression is well-documented, such as human kidney tissue or HEK-293 cells . The expected molecular weight for SLC17A5 is approximately 55 kDa (calculated from the 495 amino acid sequence), though observed molecular weights may vary, with some reports indicating bands around 31 kDa . Use Jurkat whole cell lysate as a reference, where a band at approximately 54 kDa should be observed .

For immunocytochemistry validation, compare staining patterns with existing literature, such as the cytoplasmic vesicular pattern observed in methanol-fixed HepG2 cells . Include appropriate negative controls such as secondary antibody-only stains and isotype controls. For definitive validation, consider using cell lines with SLC17A5 knockdown/knockout or those derived from patients with known SLC17A5 mutations, such as the GM08497 cell line homozygous for the c.115C>T variant . This comparative approach between wild-type and mutant/deficient samples provides compelling evidence of antibody specificity.

What sample preparation protocols should I follow for optimal SLC17A5 detection?

For Western blot analysis, prepare samples using standard SDS-PAGE protocols, typically using 10% gels which have been successfully employed in previous studies . Load approximately 30 μg of whole cell lysate per lane, as demonstrated with Jurkat cell preparations . For immunofluorescence studies, methanol fixation has been proven effective for SLC17A5 detection in HepG2 cells . This fixation method preserves the integrity of the cellular structures while maintaining the antigenicity of SLC17A5.

For immunohistochemistry on tissue sections, paraffin embedding followed by standard antigen retrieval protocols is recommended . When working with cell lines derived from patients with SLC17A5 mutations, such as human dermal fibroblasts (HDFs), standard cell culture and harvesting protocols are suitable, with no special modifications required beyond those typically used for primary cells . Regardless of application, all samples should be handled consistently to minimize experimental variability, and appropriate controls should be included in each experiment.

How can I distinguish between different SLC17A5 isoforms or mutant variants using antibodies?

Distinguishing between SLC17A5 isoforms or mutant variants requires strategic antibody selection and experimental design. First, identify the specific region or epitope recognized by your antibody. For example, the Abcam antibody ab153920 targets a recombinant fragment within human SLC17A5 amino acids 1-250 , which would detect variants with mutations outside this region but might show altered binding to variants with mutations within this region, such as the common R39C (c.115C>T) mutation associated with Salla disease .

For comprehensive analysis of variants, implement a comparative approach using multiple antibodies targeting different epitopes. This allows detection of truncated proteins or those with domain-specific mutations. When studying known mutations like the c.115C>T variant, design a Western blot experiment comparing samples from control cells (GM08497 corrected cells) alongside cells harboring homozygous mutations (untreated GM08497) and compound heterozygous variants (GM11850 with c.115C>T/c.251delC) . Supplement antibody-based detection with molecular techniques such as RT-PCR to confirm expression patterns at the mRNA level.

For definitive identification of specific variants, consider complementing antibody-based methods with mass spectrometry for precise protein characterization or using genotyped patient-derived cell lines as references, such as those available from the Coriell Institute that have been characterized for specific SLC17A5 variants .

What are the best methods to assess functional defects in SLC17A5 mutant models using antibody-based techniques?

Assessing functional defects in SLC17A5 mutant models requires a combination of antibody-based techniques with functional assays. A comprehensive approach includes:

• Lysosomal morphology assessment: Utilize immunofluorescence co-staining of SLC17A5 with lysosomal markers such as LAMP1 and CD63. Quantitative image analysis can reveal changes in lysosomal size, number, and distribution. Previous studies have observed increased intensity of these markers in cells with SLC17A5 mutations compared to controls .

• Protein localization studies: Perform subcellular fractionation followed by Western blot to determine if mutant SLC17A5 properly localizes to lysosomes or if it is retained in other cellular compartments such as the endoplasmic reticulum.

• Free sialic acid (FSA) measurement: Complement antibody detection with biochemical assays measuring FSA levels, a key functional readout for SLC17A5 deficiency. Cells with homozygous c.115C>T mutations show significantly elevated FSA (3.07 nM/mg protein) compared to corrected or unaffected cells (1.33-1.43 nM/mg protein) .

• Transport assays: Develop radioactive or fluorescently labeled substrate uptake assays to directly measure transport function in cells expressing wild-type versus mutant SLC17A5.

A comprehensive table comparing these parameters across different SLC17A5 variants would include:

This integrative approach provides a comprehensive assessment of SLC17A5 function beyond mere protein expression levels .

How can antibodies against SLC17A5 be utilized in gene therapy validation studies?

Antibodies against SLC17A5 play a crucial role in validating gene therapy approaches for sialic acid storage disorders by providing multiple layers of confirmation beyond genetic correction. In recent base editing studies targeting the common c.115C>T mutation, antibodies were essential for:

• Protein expression verification: Western blot analysis using SLC17A5 antibodies confirms successful translation of the corrected gene into protein, verifying that the genetic correction results in restored protein expression .

• Protein localization assessment: Immunofluorescence microscopy with SLC17A5 antibodies demonstrates proper subcellular localization of the corrected protein to lysosomes, confirming not just expression but appropriate trafficking .

• Functional correlation studies: Co-staining for SLC17A5 alongside lysosomal markers like LAMP1 and CD63 enables assessment of whether genetic correction normalizes lysosomal morphology and abundance. This approach revealed a downward trend in LAMP1 (from 0.21 to 0.16 mean intensity units) and CD63 (from 0.17 to 0.13 mean intensity units) in adenine base editing (ABE)-treated human dermal fibroblasts compared to affected cells, indicating partial normalization of lysosomal phenotype .

• Long-term correction monitoring: Sequential sampling with antibody detection allows tracking of the stability of genetic correction over time, critical for determining the durability of therapeutic intervention.

When designing validation protocols, implement a comprehensive panel of assessments including Western blot, immunofluorescence, and functional assays measuring free sialic acid levels. Compare these results across multiple experimental groups: untreated mutant cells, gene-corrected cells, and wild-type controls, establishing a correlation between genetic correction, protein expression/localization, and functional restoration .

What considerations should be made when studying SLC17A5 in different tissue and cell types?

Studying SLC17A5 across diverse tissues and cell types requires careful consideration of multiple factors to ensure accurate and interpretable results:

• Expression pattern variations: SLC17A5 expression differs significantly between tissues. Western blot analysis should include appropriate positive controls such as human kidney tissue and HEK-293 cells where expression is well-documented . Optimization of antibody concentration is crucial, with recommended ranges of 1:500-1:2000 for Western blotting, though this may require adjustment for tissues with lower expression levels .

• Functional diversity: SLC17A5 performs distinct functions in different cell types. In salivary gland acinar cells, it primarily functions as an electrogenic proton-coupled nitrate symporter , while in neurons, it facilitates vesicular uptake of acidic amino acids . These functional differences may manifest as altered subcellular localization, which can be assessed through immunofluorescence co-localization studies with organelle-specific markers.

• Cell-specific binding partners: SLC17A5 may interact with different proteins depending on cell type. When interpreting immunoprecipitation results, consider that co-precipitating proteins may vary between tissues, potentially affecting antibody accessibility to certain epitopes.

• Tissue-specific post-translational modifications: Glycosylation patterns or other modifications may differ between tissues, potentially affecting antibody recognition. Validation across multiple tissues is recommended to identify any tissue-specific detection issues.

• Fixation sensitivity: For immunohistochemistry and immunofluorescence applications, fixation requirements may vary by tissue type. While methanol fixation has proven effective for HepG2 cells , other cell types may require alternative fixatives to preserve SLC17A5 antigenicity while maintaining tissue architecture.

When studying neurological tissues relevant to sialic acid storage disorders, particular attention should be paid to oligodendrocyte lineage cells where SLC17A5 regulates myelinogenesis through metabolism of sialylated conjugates .

What are the optimal antibody dilutions and incubation conditions for various applications?

Optimal working conditions for SLC17A5 antibodies vary by application, vendor, and experimental system. Based on published protocols and vendor recommendations:

Western Blot (WB):

• Recommended dilution range: 1:500-1:2000

• Validated dilution examples: 1:1000 for Jurkat whole cell lysate (30 μg loading)

• Incubation conditions: Typically overnight at 4°C in blocking buffer containing PBS with 0.02% sodium azide

• Detection system: HRP-conjugated secondary antibodies with enhanced chemiluminescence detection

Immunocytochemistry/Immunofluorescence (ICC/IF):

• Recommended dilution: 1:500 for methanol-fixed HepG2 cells

• Incubation conditions: 1-2 hours at room temperature or overnight at 4°C

• Counterstaining: Compatible with nuclear stains such as Hoechst 33343

Immunohistochemistry (IHC-P):

• Recommended dilution: 1:500 for paraffin-embedded BT474 xenograft tissues

• Antigen retrieval: Heat-induced epitope retrieval recommended

• Incubation conditions: Typically overnight at 4°C

ELISA:

• Dilution range needs to be empirically determined for each system

• Published applications have utilized this technique successfully

For all applications, it is strongly recommended to perform a dilution series to determine optimal concentration for your specific experimental system, as factors such as tissue type, fixation method, and protein expression levels can significantly impact results. Store antibodies according to manufacturer recommendations, typically at -20°C in PBS with 0.02% sodium azide and 50% glycerol (pH 7.3) to maintain reactivity .

How can I troubleshoot common issues when using SLC17A5 antibodies?

When troubleshooting SLC17A5 antibody applications, researchers should address several common issues with specific solutions:

No signal or weak signal:

• Verify SLC17A5 expression in your sample through RT-PCR before antibody detection

• Increase antibody concentration or extend incubation time

• Enhance antigen retrieval for fixed tissues/cells

• Include positive controls such as human kidney tissue or HEK-293 cells

• Check secondary antibody compatibility and functionality

Multiple bands or unexpected band size:

• The calculated molecular weight for SLC17A5 is 55 kDa (from 495 amino acids), but observed weights may vary with some reports indicating bands around 31 kDa

• Validate the predicted band size of 54 kDa using Jurkat whole cell lysate

• Test antibody specificity using SLC17A5 knockout/knockdown samples

• Consider post-translational modifications or proteolytic processing that may affect migration

• Optimize gel percentage and running conditions (10% SDS-PAGE has been used successfully)

High background:

• Increase blocking time or blocker concentration

• Optimize antibody dilution through titration

• Include additional washing steps

• For immunofluorescence, include an autofluorescence reduction step

• Use more specific secondary antibodies or consider cross-adsorbed versions to reduce cross-reactivity

Inconsistent results:

• Standardize sample collection, processing, and storage conditions

• Prepare fresh buffers and reagents for each experiment

• Maintain consistent incubation times and temperatures

• Document lot numbers of antibodies and track any performance variations

• Consider batch effects when comparing samples processed on different days

When studying SLC17A5 in patient-derived cells with specific mutations, such as the c.115C>T variant associated with Salla disease, sequence verification is essential before antibody-based experiments to confirm the presence of the expected genetic variants .

What controls should be included when using SLC17A5 antibodies for different applications?

A robust experimental design with appropriate controls is essential when using SLC17A5 antibodies:

Essential Positive Controls:

• Tissue/cell-type positive controls: Human kidney tissue and HEK-293 cells have confirmed SLC17A5 expression and should be included as positive controls

• Recombinant protein: Purified SLC17A5 protein or overexpression lysates can serve as band size references

• Validated cell lines: Jurkat whole cell lysate (30 μg) has been validated to show the predicted 54 kDa band

Negative Controls:

• Antibody specificity controls:

  • Secondary antibody-only controls to assess non-specific binding

  • Isotype controls to evaluate background from primary antibody host species

  • Pre-adsorption controls where primary antibody is pre-incubated with immunizing peptide

• Biological controls:

  • SLC17A5 knockout/knockdown samples when available

  • Tissues/cells known not to express SLC17A5

Application-Specific Controls:

• For Western blot:

  • Loading controls (β-actin, GAPDH) to normalize protein amounts

  • Molecular weight markers to verify band size

  • Gradient of protein amounts to assess linear detection range

• For Immunofluorescence/IHC:

  • Co-staining with organelle markers to confirm expected subcellular localization

  • Counterstains (e.g., DAPI for nuclei, Hoechst 33343) for structural context

  • Autofluorescence controls (unstained samples)

• For studying disease-associated variants:

  • Wild-type control cells

  • Cells with known SLC17A5 mutations as reference standards

  • Genetically corrected patient cells (e.g., adenine base editing-treated cells) as functional recovery controls

Quantitation Controls:

• Standard curves for quantitative applications

• Inter-assay calibrators for experiments conducted across multiple days

• Technical replicates to assess method precision

Including this comprehensive set of controls ensures that experimental results can be interpreted with confidence and allows troubleshooting of any unexpected findings.

How should I analyze and interpret SLC17A5 antibody data in the context of disease models?

Analyzing SLC17A5 antibody data in disease model contexts requires integration of protein expression, localization, and functional assessments:

Quantitative Analysis Approaches:

• Expression level assessment: Normalize Western blot signal intensity to loading controls (β-actin, GAPDH) to accurately compare SLC17A5 protein levels between wild-type and disease models. Present data as fold-change relative to controls.

• Localization analysis: For immunofluorescence data, calculate colocalization coefficients (Pearson's, Mander's) between SLC17A5 and organelle markers to quantify subcellular distribution changes. Mislocalization often occurs in disease states even when total protein levels remain unchanged.

• Lysosomal morphology metrics: Quantify mean fluorescence intensity of lysosomal markers like LAMP1 and CD63 as demonstrated in studies of SLC17A5 c.115C>T human dermal fibroblasts, where untreated cells showed elevated LAMP1 (0.21 mean intensity units) and CD63 (0.17 mean intensity units) compared to lower values in corrected cells (0.16 and 0.13 mean intensity units, respectively) .

Correlation with Functional Readouts:

• Free sialic acid (FSA) levels: Establish correlation between SLC17A5 protein levels/localization and FSA accumulation. In c.115C>T homozygous cells, FSA levels (3.07 nM/mg protein) were significantly higher than in controls (1.43 nM/mg protein) or gene-corrected cells (1.33 nM/mg protein) .

• Genotype-phenotype correlation: Different SLC17A5 mutations produce varying disease severity. The R39C (c.115C>T) mutation in homozygosity produces milder phenotypes than compound heterozygous states or other mutations . Analyze antibody-based protein detection in conjunction with clinical severity scales for comprehensive interpretation.

Interpretation Framework:

• Compare findings across multiple model systems (patient-derived cells, animal models, in vitro systems)

• Evaluate consistency between protein-level changes and functional outcomes

• Consider gene dosage effects—homozygous versus heterozygous mutations may show different protein expression patterns

• Assess whether interventions (pharmacological, genetic correction) normalize both protein metrics and functional readouts

A comprehensive analysis table for SLC17A5 disease models should include:

This structured approach facilitates comprehensive data interpretation in the context of SLC17A5-associated diseases .

How can SLC17A5 antibodies be employed in gene editing validation studies?

SLC17A5 antibodies serve as essential tools for validating gene editing approaches targeting sialic acid storage disorders through a multi-parameter assessment strategy:

• Editing efficiency verification: Antibody-based protein detection provides crucial confirmation that genetic modifications successfully translate to the protein level. In studies employing adenine base editing (ABE) to correct the c.115C>T variant in SLC17A5, Western blot analysis using specific antibodies confirms that the genetic correction results in restored protein expression .

• Functional correlation assessment: By examining both protein expression/localization (via antibodies) and functional parameters (free sialic acid levels), researchers can establish direct links between genetic correction and phenotypic rescue. This approach demonstrated that ABE-mediated correction of the c.115C>T variant in patient-derived fibroblasts normalized free sialic acid levels from elevated (3.07 nM/mg protein) to control-equivalent levels (1.33 nM/mg protein) .

• Cellular phenotype normalization: Immunofluorescent co-staining for SLC17A5 and lysosomal markers (LAMP1, CD63) enables assessment of whether genetic correction normalizes cellular phenotypes beyond just protein expression. ABE-corrected cells showed trends toward normalization of these markers compared to untreated cells .

A comprehensive validation workflow using antibodies should include:

This multi-dimensional approach using antibodies in conjunction with functional assays provides robust validation of gene editing approaches targeting SLC17A5-associated disorders .

What are the considerations for using SLC17A5 antibodies in high-throughput screening applications?

Implementing SLC17A5 antibodies in high-throughput screening (HTS) applications requires careful optimization to ensure reliability, reproducibility, and efficient workflow:

Assay Development Considerations:

• Antibody selection: Choose antibodies with high specificity and sensitivity validated across multiple applications. For SLC17A5, antibodies recognizing conserved epitopes outside common mutation sites (like the R39C region) will provide more consistent results across different genetic variants .

• Signal optimization: Determine the optimal signal-to-noise ratio through antibody titration. While standard recommendations for Western blot applications suggest 1:500-1:2000 dilutions , HTS applications may require further optimization to minimize reagent usage while maintaining signal strength.

• Assay miniaturization: Adapt protocols to microplate formats (96-, 384-, or 1536-well) with proportional scaling of cell numbers, reagent volumes, and incubation times. This requires verification that signal detection remains linear across reduced volumes.

• Automation compatibility: Ensure protocols are amenable to liquid handling systems with standardized wash steps, incubation times, and detection methods. For immunofluorescence applications, this may involve optimization of fixation procedures compatible with robotic systems.

Detection Systems Optimization:

• High-content imaging: For screening compounds that may affect SLC17A5 localization or expression, implement multi-parameter high-content imaging that simultaneously measures:

  • SLC17A5 expression levels

  • Subcellular localization (colocalization with lysosomal markers)

  • Lysosomal morphology (size, number, distribution)

  • Cell viability markers

• Automated Western blot alternatives: Consider capillary-based protein detection systems or in-cell Westerns for higher throughput than traditional Western blotting while maintaining quantitative protein detection capabilities.

• Functional readouts: Couple antibody-based detection with high-throughput compatible functional assays, such as plate-based fluorometric assays for free sialic acid, to create multi-dimensional screening data.

Quality Control Measures:

• Positive and negative controls: Include controls on every plate, including cells with known SLC17A5 mutations (e.g., GM08497 with homozygous c.115C>T variant), wild-type controls, and genetically corrected cells as reference standards .

• Statistical validation: Implement Z'-factor calculation to assess assay quality and suitability for HTS. Aim for Z' values >0.5 for primary screens.

• Technical replication strategy: Design plate layouts with technical replicates positioned to control for positional effects and edge artifacts common in microplate assays.

Properly optimized high-throughput screening using SLC17A5 antibodies can facilitate identification of compounds or genetic interventions that normalize protein expression, localization, and function in sialic acid storage disorders.